Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hadjiev

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Leukemia & Lymphoma|October 11, 2021
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trialTara Cochrane, Alicia Enrico, David Gomez-Almaguer, et al.
The Journal of International Medical Research|February 16, 2026
Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE)Vasko Graklanov, Atanas Radinoff, Ilina Micheva, et al.
European Journal of Hybrid Imaging|June 30, 2021
ROC study and SUV threshold using quantitative multi-modal SPECT for bone imagingA H Vija, P A Bartenstein, J W Froelich, et al.
Nano Letters|August 6, 2025
Creating Extrinsic Self-Trapped Excitons by Isoelectronic Doping for Lead-Free High-Efficiency Light Emission and High-Performance X-ray ScintillatorsTao Chen, Feng Lin, Wenjun Tang, et al.
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Prilozi (Makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki)|October 13, 2019
Special Conditions in Venous Thrombembolism - Case SeriesMarijan Bosevski, Irena Mitevska, Marica Pavkovic, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
JAMA|February 18, 2015
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Small (Weinheim an Der Bergstrasse, Germany)|January 21, 2022
Integration of Highly Luminescent Lead Halide Perovskite Nanocrystals on Transparent Lead Halide Nanowire Waveguides through Morphological Transformation and Spontaneous Growth in WaterTao Chen, Chong Wang, Xinxin Xing, et al.
Advanced Materials (Deerfield Beach, Fla.)|June 25, 2019
Extrinsic Green Photoluminescence from the Edges of 2D Cesium Lead HalidesChong Wang, Yanan Wang, Xinghua Su, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Leukemia & Lymphoma|October 11, 2021
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trialTara Cochrane, Alicia Enrico, David Gomez-Almaguer, et al.
The Journal of International Medical Research|February 16, 2026
Real-world disease characteristics and frontline treatments used in chronic lymphocytic leukaemia in Bulgaria: An observational cohort study (DESCRIBE)Vasko Graklanov, Atanas Radinoff, Ilina Micheva, et al.
European Journal of Hybrid Imaging|June 30, 2021
ROC study and SUV threshold using quantitative multi-modal SPECT for bone imagingA H Vija, P A Bartenstein, J W Froelich, et al.
Nano Letters|August 6, 2025
Creating Extrinsic Self-Trapped Excitons by Isoelectronic Doping for Lead-Free High-Efficiency Light Emission and High-Performance X-ray ScintillatorsTao Chen, Feng Lin, Wenjun Tang, et al.
American Journal of Hematology|August 2, 2017
Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Prilozi (Makedonska Akademija Na Naukite I Umetnostite. Oddelenie Za Medicinski Nauki)|October 13, 2019
Special Conditions in Venous Thrombembolism - Case SeriesMarijan Bosevski, Irena Mitevska, Marica Pavkovic, et al.
American Journal of Hematology|June 23, 2021
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
JAMA|February 18, 2015
Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trialPramod K Mistry, Elena Lukina, Hadhami Ben Turkia, et al.
Small (Weinheim an Der Bergstrasse, Germany)|January 21, 2022
Integration of Highly Luminescent Lead Halide Perovskite Nanocrystals on Transparent Lead Halide Nanowire Waveguides through Morphological Transformation and Spontaneous Growth in WaterTao Chen, Chong Wang, Xinxin Xing, et al.
Advanced Materials (Deerfield Beach, Fla.)|June 25, 2019
Extrinsic Green Photoluminescence from the Edges of 2D Cesium Lead HalidesChong Wang, Yanan Wang, Xinghua Su, et al.
Pageof 16